Hyperglycemia, Hypertension, and Dyslipidemia in Type 2 Diabetes Mellitus: Goals for Diabetes Management

Clinical Cornerstone

Volumn 9, Issue SUPPL. 2, 2008, Pages

  LeRoith, Derek ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; SULFONYLUREA; TARANABANT; THIAZIDE DIURETIC AGENT;

ANTIINFLAMMATORY ACTIVITY; ANXIETY; ARTICLE; BLOOD PRESSURE REGULATION; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIMARY PREVENTION; RISK FACTOR; SIDE EFFECT; STROKE;

EID: 65449122405     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)60021-1     Document Type: Article

References (46)

1. Chobanian A.V., Bakris G.L., Black H.R., et al., for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA 289 (2003) 2560-2572
2. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 Suppl 1 (2008) S12-S54
3. Berry C., Tardif J.C., and Bourassa M.G. Coronary heart disease in patients with diabetes: Part I: Recent advances in prevention and noninvasive management. J Am Coll Cardiol 49 (2007) 631-642
4. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
5. Adler A.I., Stratton I.M., Neil H.A., et al., for the UK Prospective Diabetes Study (UKPDS) Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study [published correction appears in BMJ. 2001;322:90]. BMJ 321 (2000) 412-419
6. Holman R.R., Paul S.K., and Bethel M.A. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359 (2008) 1565-1576
7. Gotto Jr. A.M. Cardiologist's role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus. Am J Cardiol 99 (2007) 3B-5B
8. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
9. Buse J.B., Ginsberg H.N., Bakris G.L., et al., for the American Heart Association and the American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30 (2007) 162-172
10. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 Suppl 1 (2007) 1-68
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
12. Saaddine J.B., Cadwell B., Gregg E.W., et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144 (2006) 465-474
13. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
14. National Committee for Quality Assurance. The State of Health Care Quality 2007 (2007), National Committee for Quality Assurance, Washington, DC
15. Bodenheimer T. A 63-year-old man with multiple cardiovascular risk factors and poor adherence to treatment plans. JAMA 298 (2007) 2048-2055
16. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 30 (2007) 2399-2400
17. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
18. LeRoith D., and Smith D.O. Monitoring glycemic control: The cornerstone of diabetes care. Clin Ther 27 (2005) 1489-1499
19. Wood S. Hba1c out, average glucose in? ADAG results support new reference method for chronic glycemia. Heartwire, September 19, 2007. http://www.medscape.com/viewarticle/563059 Accessed May 15, 2008.
20. Fonseca V.A. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med 120 Suppl 2 (2007) S18-S25
21. Fonseca V., Desouza C., Asnani S., and Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25 (2004) 153-175
22. Muntner P., He J., Chen J., et al. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: Analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 14 (2004) 686-695
23. Sobel B.E. Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med 120 Suppl 2 (2007) S3-S11
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558]. Lancet 352 (1998) 854-865
25. Holman R.R., Paul S.K., Bethel M.A., et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008) 1577-1589
26. Mazzone T. Prevention of macrovascular disease in patients with diabetes mellitus: Opportunities for intervention. Am J Med 120 Suppl 2 (2007) S26-S32
27. Dormandy J.A., Charbonnel B., Eckland D.J., et al., for the PROactive Investigators. Secondary prevention of macro-vascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366 (2005) 1279-1289
28. Erdmann E., Dormandy J.A., Charbonnel B., et al., for the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) study. J Am Coll Cardiol 49 (2007) 1772-1780
29. Inzucchi S.E., Masoudi F.A., Wang Y., et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project. Diabetes Care 28 (2005) 1680-1689
30. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357:100]. N Engl J Med 356 (2007) 2457-2471
31. ADVANCE diabetes trial results confirm no evidence of safety risk. http://www.eurekalert.org/pub_releases/2008-02/uom-edt022808php Accessed October 20, 2008.
32. Cefalu W.T., and Watson K. Intensive glycemic control and cardiovascular disease observations from the ACCORD study: Now what can a clinician possibly think?. Diabetes 57 (2008) 1163-1165
33. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: United States, 2005. http://www.cdc.gov/diabetes/pubs/factsheet05.htm Accessed May 16, 2008.
34. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
35. Eguchi K., Ishikawa J., Hoshide S., et al. Impact of blood pressure vs. glycemic factors on target organ damage in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 8 (2006) 404-410
36. Eguchi K., Ishikawa J., Hoshide S., et al. Masked hypertension in diabetes mellitus: A potential risk. J Clin Hypertens (Greenwich) 9 (2007) 601-607
37. Leitão C.B., Canani L.H., Kramer C.K., et al. Masked hypertension, urinary albumin excretion rate, and echocardiographic parameters in putatively normotensive type 2 diabetic patients. Diabetes Care 30 (2007) 1255-1260
38. Stone N.J., Bilek S., and Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and options. Am J Cardiol 96 (2005) 53E-59E
39. Jensen M.D. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?. Am J Med 120 Suppl 1 (2007) S25-S31 discussion S31-S32.
40. Jensen M.D. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring) 14 Suppl 3 (2006) 143S-149S
41. Scheen A.J., Finer N., Hollander P., et al., for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study [published correction appears in Lancet. 2006;368:1650]. Lancet 368 (2006) 1660-1672
42. Addy C., Wright H., Van Laere K., et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7 (2008) 68-78
43. Nissen S.E., Nicholls S.J., Wolski K., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The STRADIVARIUS randomized controlled trial. JAMA 299 (2008) 1547-1560
44. ZimultiAcompliaReport. Merck halts development of its diet drug taranabant. http://www.acompliareport.com/New/news-100208.htm Accessed October 20, 2008.
45. Fong T.M., Guan X.M., Marsh D.J., et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S, 2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5- (trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 321 (2007) 1013-1022
46. Doggrell S.A. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?. Exp Opin Invest Drugs 14 (2005) 339-342